

MPLA-SM

Monophosphoryl Lipid A from *S. minnesota* R595; TLR4 ligand

Catalog code: tlr1-mpla

<https://www.invivogen.com/mpla>

For research use only

Version 24J21-NJ

PRODUCT INFORMATION

Contents

- 1 mg Monophosphoryl Lipid A (MPLA-SM)

Storage

- MPLA-SM is provided lyophilized and shipped at room temperature. Store at -20°C. Lyophilized product is stable for 1 year when properly stored.
- Upon resuspension, prepare aliquots of MPLA-SM and store at -20°C. Resuspended product is stable for 6 months when properly stored. Avoid repeated freeze-thaw cycles.

Quality control

- Biological activity is validated using cellular assays.
- The absence of other bacterial components (e.g. lipoproteins) is controlled using HEK-Blue™ TLR2 cells.

PRODUCT DESCRIPTION

MPLA-SM is a preparation of Monophosphoryl Lipid A (MPLA) derived from the lipopolysaccharide (LPS) of *Salmonella minnesota* R595 (Re mutant). InvivoGen's MPLA-SM is a potent Toll-like receptor 4 (TLR4) agonist. Importantly, it is free of TLR2-activating contaminants.

MPLA-SM triggers human and mouse TLR4 responses, although with varying activity on human TLR4. The complexity of the process for natural extraction of MPLA-SM from LPS generates multiple hexa-acylated and under-acylated congeneric forms. This congener mix is responsible for different TLR4 agonist potency of each preparation¹.

Note: MPLA-SM lots that display a higher potency for human TLR4 are denoted with an asterisk (MPLA-SM*, cat code tlr1-mpla2).

PRODUCT PROPERTIES

Specificity: Human and mouse TLR4 agonist

Working concentration: 3 ng -1 µg/ml (HEK-Blue™ hTLR4 cells)
10 pg -100 ng/ml (HEK-Blue™ mTLR4 cells)

Appearance: Clear lipidic film

Solubility: 1 mg/ml in DMSO

BACKGROUND

Monophosphoryl Lipid A (MPLA) is a natural compound derived from the lipopolysaccharide (LPS) component of the cell wall of Gram-negative bacteria. LPS is a potent activator of the immune system. Its recognition by Toll-like receptor 4 (TLR4) leads to NF-κB and IRF activation and the production of proinflammatory cytokines and interferons, respectively². Thus, LPS features many characteristics needed for an effective vaccine adjuvant. However, large uncontrolled amounts of LPS are extremely toxic and can cause devastating diseases³.

Wild-type LPS, referred to as smooth (sLPS) comprises three covalently linked regions: a Lipid A backbone, an oligosaccharide core, and O-polysaccharide chains. Some bacteria produce a truncated LPS, without O-side chains, referred to as rough (rLPS)⁴.

LPS biological activity is mediated through Lipid A recognition by TLR4 and is commensurate to number of Lipid A fatty acyl chains³. Hexa-acylated (6 chains) Lipid A is a highly potent TLR4 agonist, while under-acylated (4-5 chains) Lipid A induces lower or antagonistic responses⁵.

Acidic extraction of Lipid A from LPS produces MPLA, which displays reduced toxicity while retaining the ability to activate TLR4^{6,7}. The reduced toxicity of MPLA is attributed to the preferential triggering of the IRF pathway upon TLR4 activation, resulting in decreased induction of inflammatory cytokines⁵.

METHODS

Preparation of stock suspension (1 mg/ml)

- Add 1 ml of DMSO and vortex until completely resuspended.
- Prepare aliquots of stock solution and store at -20°C. Further dilutions can be prepared using water.

Notes:

- The suspension may appear to contain floating fine particles. Sonication may help to disperse these particles.
- Alternatively, MPLA-SM can be resuspended in DMSO containing 0.2% triethylamine.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: info@invivogen.com

TLR4 activation using MPLA-SM

MPLA-SM can be used to activate TLR4 in HEK-Blue™ hTLR4 cells, that were designed to study TLR4 stimulation by monitoring NF-κB activation. Stimulation of HEK-Blue™ hTLR4 cells with a TLR4 agonist activates NF-κB which induces the production of SEAP (secreted embryonic alkaline phosphatase). Levels of SEAP can be easily determined using a [HEK-Blue™ Detection](#), a cell culture medium that allows the detection of SEAP in the supernatant.

For more information visit: <https://www.invivogen.com/hek-blue-trl4>

- Add 20 µl of MPLA-SM at various concentrations in a well of a 96-well plate.
- Add 180 µl of HEK-Blue™ hTLR4 cell suspension per well.
- Incubate the plate for 16-24 h at 37°C, 5% CO₂.
- Determine SEAP levels using a spectrophotometer at 620-655 nm.

1. Wang YQ, et al., 2020. MPL Adjuvant Contains Competitive Antagonists of Human TLR4. *Front. Immunol.* 11:577823. 2. Kuzmich, NN, et al., 2017. TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis. *Vaccines (Basel)* 5(1):165-22. 3. Steimle, A, et al., 2016. Structure and function: Lipid A modifications in commensals and pathogens. *Int J Med Microbiol* 306, 290-301. 4. Raetz CR. 1990. Biochemistry of endotoxins. *Annu. Rev. Biochem.* 59, 129-70. 5. Cochet, F. & Peri, F. 2017. The role of carbohydrates in the lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling. *Int J Mol Sci* 18. 6. Qureshi N, et al., 1982. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of *Salmonella typhimurium*. *J. Biol. Chem.*, 257:11808-15. 7. Romero CD, et al., 2011. The Toll-Like Receptor 4 agonist monophosphoryl Lipid A augments innate host resistance to systemic bacterial infection. *Infect Immun.* 79:3576-3587. 8. Mata-Haro V, et al., 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. *Science*. 316(5831):1628-32.

RELATED PRODUCTS

Product	Catalog Code
HEK-Blue™ hTLR4 Cells (human TLR4)	hkb-htrl4
HEK-Blue™ mTLR4 Cells (mouse TLR4)	hkb-mtrl4
LPS-EB Ultrapure (LPS from <i>E. coli</i> 0111:B4)	tlrl-3pelps
LPS-EK Ultrapure (LPS from <i>E. coli</i> K12)	tlrl-pekips
MPLA-SM VacciGrade™	vac-mpla
MPLAs (synthetic MPLA)	tlrl-mpls
MPLAs VacciGrade™	vac-mplas
HEK-Blue™ Detection	hb-det2

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com

